[go: up one dir, main page]

Li et al., 2021 - Google Patents

The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy

Li et al., 2021

View PDF
Document ID
1470575358635200184
Author
Li J
Liu B
Publication year
Publication venue
Cytokine & growth factor reviews

External Links

Snippet

Emerging evidence has documented that multisystem organ failure in coronavirus disease 2019 (COVID-19) patients is strongly associated with various coagulopathies. Treatments for COVID-19-associated coagulopathy are still a clinical challenge. An advancement in the …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Frantzeskaki et al. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation
Iba et al. Thromboinflammation in acute injury: infections, heatstroke, and trauma
Bonaventura et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
Castro et al. Is the endothelium the missing link in the pathophysiology and treatment of COVID-19 complications?
Ghadimi et al. Perioperative management of the bleeding patient
Sniecinski et al. Activation of the hemostatic system during cardiopulmonary bypass
Visser et al. Role of factor XIa and plasma kallikrein in arterial and venous thrombosis
Valencia et al. Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus
Alnima et al. COVID-19 coagulopathy: from pathogenesis to treatment
Kim et al. Chronic rhinosinusitis and the coagulation system
Lippi et al. C-reactive protein and venous thromboembolism: causal or casual association?
Li et al. The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy
Liu et al. Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets
Undas Fibrinolysis in venous thromboembolism
EP2340028A1 (en) Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
Kau et al. Activated protein C ameliorates Bacillus anthracis lethal toxin-induced lethal pathogenesis in rats
Kwaan Microvascular thrombosis: a serious and deadly pathologic process in multiple diseases
Lio et al. Coagulopathy in COVID-19
Mochizuki et al. Visualization of domain-and concentration-dependent impact of thrombomodulin on differential regulation of coagulation and fibrinolysis
US20250099540A1 (en) Methods and pharmaceutical composition for treating thrombotic disorders
Aydemir et al. The role of the oxidative stress-inflammation axis in the COVID-19-infected patients with Chagas disease: a key parameter to be considered during the pandemic
TW202130362A (en) Neutrophil activation regulator
Katneni et al. Consumptive Coagulopathy and Thrombosis during severe COVID-19 infection: Potential Involvement of VWF/ADAMTS13
Prouse et al. Alternate functions of physiological anticoagulants
Wan et al. Protective effects of tissue factor pathway inhibitor on mice with lipopolysaccharide-induced acute lung injury